PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTazobactam
Zosyn, Zerbaxa(tazobactam)
Piperacillin / Tazobactam, Zerbaxa, Zosyn (tazobactam) is a small molecule pharmaceutical. Tazobactam was first approved as Zosyn on 1993-10-22. It has been approved in Europe to treat bacterial infections.
Download report
Favorite
COVID-19
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
Combinations
Piperacillin tazobactam, Zerbaxa, Zosyn (discontinued: Piperacillin tazobactam, Zosyn)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Piperacillin sodium
+
Tazobactam sodium
Tradename
Company
Number
Date
Products
ZOSYN IN PLASTIC CONTAINERBaxterN-050750 RX1998-02-24
3 products, RLD, RS
Show 1 discontinued
Ceftolozane sulfate
+
Tazobactam sodium
Tradename
Company
Number
Date
Products
ZERBAXACubist PharmaceuticalsN-206829 RX2014-12-19
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
piperacillin and tazobactamANDA2025-02-26
piperacillin sodium and tazobactam sodiumANDA2024-12-10
piperacillin, tazobactamANDA2024-08-31
zerbaxaNew Drug Application2024-11-04
zosynNew Drug Application2024-12-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pneumoniaEFO_0003106D011014J18
urinary tract infectionsEFO_0003103D014552N39.0
bacterial infections—D001424A49
intraabdominal infections—D059413—
pseudomonas infectionsEFO_0001076D011552A41.52
infectious skin diseases—D012874—
escherichia coli infectionsEFO_1001318D004927B96.20
pelvic infection—D034161—
soft tissue infections—D018461—
streptococcal infectionsEFO_1001476D013290—
Show 3 more
Agency Specific
FDA
EMA
Expiration
Code
CEFTOLOZANE SULFATE / TAZOBACTAM SODIUM, ZERBAXA, CUBIST PHARMS LLC
2025-04-21NPP
2024-12-19GAIN
2019-12-19NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Ceftolozane Sulfate / Tazobactam Sodium, Zerbaxa, Cubist Pharms Llc
101251492035-08-14DP
103764962034-09-09U-2610, U-2611
109330532034-09-09U-3090, U-3091
89068982034-05-28DS, DP
89687532034-03-14U-1672, U-1673, U-3360, U-3361
93207402034-03-14DP
98729062034-03-14DP
104208412034-03-14U-1672, U-2631, U-3360, U-3361
112786222034-03-14U-3335, U-3336
84764252032-09-27DP
86859572032-09-27DPU-36
97243532032-09-07U-2565, U-2566
100289632032-09-07U-2565, U-2566
71292322028-05-15DS, DPU-36, U-1676, U-3360, U-3361
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01C: Beta-lactam antibacterials, penicillins
— J01CG: Beta-lactamase inhibitors, systemic penicillins
— J01CG02: Tazobactam
HCPCS
Code
Description
J0695
Injection, ceftolozane 50 mg and tazobactam 25 mg
J2543
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)
Clinical
Clinical Trials
221 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544———1——1
Urinary tract infectionsD014552EFO_0003103N39.0——1——1
Communicable diseasesD003141————1——1
PyelonephritisD011704EFO_1001141N10-N16——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437—N191————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTazobactam
INNtazobactam
Description
Tazobactam is a member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections. It has a role as an antimicrobial agent, an antiinfective agent and an EC 3.5.2.6 (beta-lactamase) inhibitor. It is a member of penicillanic acids and a member of triazoles. It is functionally related to a sulbactam. It is a conjugate acid of a tazobactam(1-).
Classification
Small molecule
Drug classbeta-lactamase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
Identifiers
PDB—
CAS-ID89786-04-9
RxCUI—
ChEMBL IDCHEMBL404
ChEBI ID9421
PubChem CID123630
DrugBankDB01606
UNII IDSE10G96M8W (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zosyn – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Zerbaxa – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Tazobactam
+
Piperacillin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 38,888 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
21,590 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use